Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults

INTRODUCTION: COBI, a PK enhancer with no ARV activity is a more selective cytochrome P450 (CYP)3A inhibitor than ritonavir (RTV), does not induce CYP isozymes, and thus has less potential for drug-drug interactions. COBI boosts DRV PK as effectively as RTV in healthy volunteers. MATERIALS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashima, Karen, Crofoot, Gordon, Tomaka, Frank L, Kakuda, Thomas N, Brochot, Anne, Vanveggel, Simon, Opsomer, Magda, Garner, William, Margot, Nicolas, Custodio, Joseph M, Fordyce, Marshall W, Szwarcberg, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P240
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225446/
https://www.ncbi.nlm.nih.gov/pubmed/25397516
http://dx.doi.org/10.7448/IAS.17.4.19772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225446/
https://www.ncbi.nlm.nih.gov/pubmed/25397516
http://dx.doi.org/10.7448/IAS.17.4.19772

Ejemplares similares